KNSA (Kiniksa Pharmaceuticals International) Current Deferred Taxes Liabilities: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KNSA Kiniksa Pharmaceuticals International PLC KNSA
50 GF Score
Price $78.63
GF Value $55.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Current Deferred Taxes Liabilities?

Kiniksa Pharmaceuticals International KNSA +0.70% 50 Current Deferred Taxes Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus rates KNSA with a GF Score™ of 50/100 and a GF Value™ of $55.19 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Kiniksa Pharmaceuticals International's current deferred tax liabilities for the quarter that ended in Jun. 2026 was $0.0 Mil.

Kiniksa Pharmaceuticals International Current Deferred Taxes Liabilities Related Terms

Kiniksa Pharmaceuticals International Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Current Deferred Taxes Liabilities Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kiniksa Pharmaceuticals International Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KNSA
50GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.0 Mil mean?
Kiniksa Pharmaceuticals International (KNSA) has a Current Deferred Taxes Liabilities of $0.0 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Kiniksa Pharmaceuticals International and its competitors.
Is Kiniksa Pharmaceuticals International's Current Deferred Taxes Liabilities too high?
Kiniksa Pharmaceuticals International's current Current Deferred Taxes Liabilities is $0.0 Mil. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Current Deferred Taxes Liabilities compare to AMRX and LQDA?
Kiniksa Pharmaceuticals International's Current Deferred Taxes Liabilities of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Drug Manufacturers company?
A good Current Deferred Taxes Liabilities depends on the Drug Manufacturers industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current Current Deferred Taxes Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $55.19, compared to a current price of $78.63 — trading 42.5% above its estimated fair value. The current Current Deferred Taxes Liabilities is $0.0 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Current Deferred Taxes Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $78.63 is trading 42.5% above its estimated GF Value™ of $55.19. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Current Deferred Taxes Liabilities: $0.0 Mil
  • GF Value™: $55.19 vs. price of $78.63 (42.5% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for KNSA

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$78.63
Price
$55.19
GF Value